facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2022
vol. 109
 
Share:
Share:
abstract:
Review article

Treatment of diseases associated with cicatricial alopecia

Lidia Rudnicka
1
,
Agnieszka Kaczorowska
1
,
Anna Waśkiel-Burnat
1
,
Adriana Rakowska
1
,
Małgorzata Olszewska
1

  1. Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
    Katedra i Klinika Dermatologiczna, Warszawski Uniwersytet Medyczny, Warszawa, Polska
Dermatol Rev/Przegl Dermatol 2022, 109, 32-42
Online publish date: 2022/05/31
View full text Get citation
 
PlumX metrics:
Cicatricial (scarring) alopecia may result from perifollicular inflammation that destroys hair follicles and replaces them with connective tissue (primary cicatricial alopecia) or from damage done to follicles by other pathology that is not primarily directed against follicles (secondary cicatricial alopecia). Examples of such pathologies are: cutaneous tuberculosis, favus, morphea en coup de sabre. Hair follicle atrophy with clinical, trichoscopic and histological features of follicular drop out can also occur in the very late stage of non-cicatricial alopecia (e.g. androgenetic alopecia, alopecia areata). The fourth group of diseases with a similar clinical and sometimes also similar trichoscopic presentation, but of significantly different histology, is alopecia associated with neoplastic diseases (alopecia neoplastica). In this article, basic information about therapeutic methods that can be applied in selected diseases associated with cicatricial alopecia, with particular emphasis on primary cicatricial alopecia, has been summarized.
keywords:

treatment of cicatricial alopecia, cicatricial alopecia, hair diseases



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.